Findings

What do systematic reviews say?

3 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Alkylating agents vs steroids, placebo or both

Clinical relapse · SSNS in children

Alkylating agents probably leads to lower relapse at 6 to 12 months compared with steroids, placebo or both (moderate certainty).

2 findings from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.44 [0.32, 0.6]
6 studies · 202 participants
Moderate
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.2 [0.09, 0.46]
4 studies · 59 participants
Low

Alkylating agents vs cyclosporin

Clinical relapse · SSNS in children

Alkylating agents may leads to lower relapse at 12 to 24 months compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.51 [0.35, 0.74]
2 studies · 95 participants
Low

Alkylating agents vs cyclosporin

Relapse at end of therapy (6 to 9 months) · SSNS in children

Alkylating agents showed no clear difference in relapse at end of therapy (6 to 9 months) compared with cyclosporin (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.91 [0.55, 1.48]
2 studies · 95 participants
Low